Antimicrobial non-susceptibility of Escherichia coli from outpatients and patients visiting emergency rooms in Taiwan

PLoS ONE

Volumn 10, Issue 12, 2015, Pages

  Wang, Jann Tay ^a,b   Chang, Shan Chwen ^a,c   Chang, Feng Yee ^d,e   Fung, Chang Phone ^f   Chuang, Yin Ching ^g   Chen, Yao Shen ^h,i   Shiau, Yih Ru ^b   Tan, Mei Chen ^b   Wang, Hui Ying ^b   Lai, Jui Fen ^b   Huang, I Wen ^b   Lauderdale, Tsai Ling Yang ^b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^e NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^f TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^g CHI MEI MEDICAL CENTER   (Taiwan)

^h KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

ⁱ NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE AMPC; CARBAPENEMASE; CEFAZOLIN; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFUROXIME; CIPROFLOXACIN; COTRIMOXAZOLE; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; FOSFOMYCIN; GENTAMICIN; IMIPENEM; NITROFURANTOIN; TETRACYCLINE; TIGECYCLINE; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BLOOD SAMPLING; EMERGENCY WARD; ESCHERICHIA COLI; HUMAN; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MULTIPLEX POLYMERASE CHAIN REACTION; OUTPATIENT; PEDIATRICS; PREVALENCE; PSEUDOMONAS AERUGINOSA; TAIWAN; URINALYSIS; ADOLESCENT; ADULT; AGED; CHILD; DRUG EFFECTS; FEMALE; GENETICS; HOSPITAL EMERGENCY SERVICE; ISOLATION AND PURIFICATION; MALE; MIDDLE AGED; PRESCHOOL CHILD; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, BACTERIAL; EMERGENCY SERVICE, HOSPITAL; ESCHERICHIA COLI; FEMALE; HUMANS; MALE; MIDDLE AGED; OUTPATIENTS; TAIWAN; YOUNG ADULT;

EID: 84956625938     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0144103     Document Type: Article

References (51)

1. Kaper JB, Nataro JP, Mobley HL. Pathogenic Escherichia coli. Nat Rev Microbiol. 2004; 2(2):123-40. Epub 2004/03/26. doi: 10.1038/nrmicro818 PMID: 15040260.
2. Foxman B. The epidemiology of urinary tract infection. Nat Rev Urol. 2010; 7(12):653-60. doi: 10.1038/nrurol.2010.190 PMID: 21139641.
3. WHO. Technical consultation: strategies for global surveillance of antimicrobial resistance. http://apps.who.int/iris/bitstream/10665/90975/1/WHO-HSE-PED-2013.10358-eng.pdf. (2 March 2015, date last accessed).2013. Available from: http://apps.who.int/iris/bitstream/10665/90975/1/WHO-HSE-PED-2013.10358-eng.pdf.
4. Harbarth S, Garbino J, Pugin J, Romand JA, Lew D, Pittet D. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med. 2003; 115(7):529-35. PMID: 14599631
5. Hooton TM. Clinical practice. Uncomplicated urinary tract infection. N Engl J Med. 2012; 366(11):1028-37. doi: 10.1056/NEJMcp1104429 PMID: 22417256
6. Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJ, Baron EJ, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis. 2010; 50(2):133-64. doi: 10.1086/649554 PMID: 20034345.
7. Theuretzbacher U, Van Bambeke F, Canton R, Giske CG, Mouton JW, Nation RL, et al. Reviving old antibiotics. J Antimicrob Chemother. 2015; 70(8):2177-81. doi: 10.1093/jac/dkv157 PMID: 26063727.
8. Bouchillon SK, Badal RE, Hoban DJ, Hawser SP. Antimicrobial susceptibility of inpatient urinary tract isolates of gram-negative bacilli in the United States: results from the study for monitoring antimicrobial resistance trends (SMART) program: 2009-2011. Clin Ther. 2013; 35(6):872-7. doi: 10.1016/j.clinthera.2013.03.022 PMID: 23623624.
9. Sanchez GV, Baird AM, Karlowsky JA, Master RN, Bordon JM. Nitrofurantoin retains antimicrobial activity against multidrug-resistant urinary Escherichia coli from US outpatients. J Antimicrob Chemother. 2014; 69(12):3259-62. doi: 10.1093/jac/dku282 PMID: 25063776.
10. Allocati N, Masulli M, Alexeyev MF, Di Ilio C. Escherichia coli in Europe: an overview. Int J Environ Res Public Health. 2013; 10(12):6235-54. doi: 10.3390/ijerph10126235 PMID: 24287850; PubMed Central PMCID: PMC3881111.
11. Hanson ND, Moland ES, Hong SG, Propst K, Novak DJ, Cavalieri SJ. Surveillance of community-based reservoirs reveals the presence of CTX-M, imported AmpC, and OXA-30 β-lactamases in urine isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. community. Antimicrob Agents Chemother. 2008; 52(10):3814-6. doi: 10.1128/aac.00877-08 PubMed Central PMCID: PMC2565870. PMID: 18663030
12. Tansarli GS, Poulikakos P, Kapaskelis A, Falagas ME. Proportion of extended-spectrum β-lactamase (ESBL)-producing isolates among Enterobacteriaceae in Africa: evaluation of the evidence - systematic review. J Antimicrob Chemother. 2014; 69(5):1177-84. doi: 10.1093/jac/dkt500 PMID: 24398340
13. Pitout JD. Enterobacteriaceae that produce extended-spectrum β-lactamases and AmpC β-lactamases in the community: the tip of the iceberg? Curr Pharm Des. 2013; 19(2):257-63. PMID: 22934977
14. Balode A, Punda-Polic V, Dowzicky MJ. Antimicrobial susceptibility of gram-negative and gram-positive bacteria collected from countries in Eastern Europe: results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) 2004-2010. Int J Antimicrob Agents. 2013; 41(6):527-35. doi: 10.1016/j.ijantimicag.2013.02.022 PMID: 23590898
15. Pascual V, Ortiz G, Simo M, Alonso N, Garcia MC, Xercavins M, et al. Epidemiology and risk factors for infections due to AmpC β-lactamase-producing Escherichia coli. J Antimicrob Chemother. 2015; 70(3):899-904. doi: 10.1093/jac/dku468 PMID: 25468902
16. Zhang J, Zheng B, Zhao L, Wei Z, Ji J, Li L, et al. Nationwide high prevalence of CTX-M and an increase of CTX-M-55 in Escherichia coli isolated from patients with community-onset infections in Chinese county hospitals. BMC Infect Dis. 2014; 14:659. doi: 10.1186/s12879-014-0659-0 PubMed Central PMCID: PMC4265337. PMID: 25466590
17. Bouchillon S, Hoban DJ, Badal R, Hawser S. Fluoroquinolone resistance among gram-negative urinary tract pathogens: global SMART program results, 2009-2010. Open Microbiol J. 2012; 6:74-8. doi: 10.2174/1874285801206010074 PubMed Central PMCID: PMC3447161. PMID: 23002406
18. European Center for Disease Prevention and Control. http://ecdc.europa.eu/en/healthtopics/antimicrobial-resistance/database/Pages/graph-reports.aspx. European Center for Disease Prevention and Control. 2015.
19. Ironmonger D, Edeghere O, Bains A, Loy R, Woodford N, Hawkey PM. Surveillance of antibiotic susceptibility of urinary tract pathogens for a population of 5.6 million over 4 years. J Antimicrob Chemother. 2015; 70(6):1744-50. doi: 10.1093/jac/dkv043 PMID: 25733586.
20. Kahlmeter G, Poulsen HO. Antimicrobial susceptibility of Escherichia coli from community-acquired urinary tract infections in Europe: the ECO.SENS study revisited. Int J Antimicrob Agents. 2012; 39(1):45-51. doi: 10.1016/j.ijantimicag.2011.09.013 PMID: 22055529.
21. th Informational Supplement M100-S24. CLSI, Wayne, PA, USA,. 2014.
22. Kuo SC, Chen PC, Shiau YR, Wang HY, Lai JFs, Huang W, et al. Levofloxacin-resistant Haemophilus influenzae, Taiwan, 2004-2010. Emerg Infect Dis. 2014; 20(8):1386-90. doi: 10.3201/eid2008.140341 PubMed Central PMCID: PMC4111205. PMID: 25061696
23. Wang JT, Chen PC, Chang SC, Shiau YR, Wang HY, Lai JF, et al. Antimicrobial susceptibilities of Proteus mirabilis: a longitudinal nationwide study from the Taiwan surveillance of antimicrobial resistance (TSAR) program. BMC Infect Dis. 2014; 14:486. doi: 10.1186/1471-2334-14-486 PMID: 25192738; PubMed Central PMCID: PMC4162950.
24. CLSI. Abbreviated Identification of Bacteria and Yeast; Approved Guideline - Second Edition M35-A2. CLSI, Wayne, PA, USA. 2008.
25. Edberg SC, Trepeta RW. Rapid and economical identification and antimicrobial susceptibility test methodology for urinary tract pathogens. J Clin Microbiol. 1983; 18(6):1287-91. PubMed Central PMCID: PMC272894. PMID: 6361049
26. CTX-M genes in Enterobacteriaceae. APMIS. 2007; 115(12):1400-8. doi: 10.1111/j.1600-0463.2007.00722.x PMID: 18184411.
27. Perez-Perez FJ, Hanson ND. Detection of plasmid-mediated AmpC β-lactamase genes in clinical isolates by using multiplex PCR. J Clin Microbiol. 2002; 40(6):2153-62. PMID: 12037080; PubMed Central PMCID: PMC130804.
28. Queenan AM, Bush K. Carbapenemases: the versatile β-lactamases. Clin Microbiol Rev. 2007; 20(3):440-58, table of contents. doi: 10.1128/cmr.00001-07 PMID: 17630334; PubMed Central PMCID: PMC1932750.
29. O'Brien TF, Stelling J. Integrated multilevel surveillance of the world's infecting microbes and their resistance to antimicrobial agents. Clin Microbiol Rev. 2011; 24(2):281-95. doi: 10.1128/CMR.00021-10 PMID: 21482726; PubMed Central PMCID: PMC3122493.
30. Karlowsky JA, Adam HJ, Baxter MR, Lagace-Wiens PR, Walkty AJ, Hoban DJ, et al. In vitro activity of ceftaroline-avibactam against gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals from 2010 to 2012: results from the CANWARD surveillance study. Antimicrob Agents Chemother. 2013; 57(11):5600-11. doi: 10.1128/aac.01485-13 PMID: 23979759; PubMed Central PMCID: PMC3811279.
31. Oteo J, Perez-Vazquez M, Campos J. Extended-spectrum β-lactamase producing Escherichia coli: changing epidemiology and clinical impact. Curr Opin Infect Dis. 2010; 23(4):320-6. PMID: 20614578.
32. Brolund A. Overview of ESBL-producing Enterobacteriaceae from a Nordic perspective. Infect Ecol Epidemiol. 2014; 4. doi: 10.3402/iee.v4.24555 PubMed Central PMCID: PMC4185132.
33. Carbonne A, Arnaud I, Maugat S, Marty N, Dumartin C, Bertrand X, et al. National multidrug-resistant bacteria (MDRB) surveillance in France through the RAISIN network: a 9 year experience. J Antimicrob Chemother. 2013; 68(4):954-9. doi: 10.1093/jac/dks464 PMID: 23194721
34. D'Andrea MM, Arena F, Pallecchi L, Rossolini GM. CTX-M-type β-lactamases: a successful story of antibiotic resistance. Int J Med Microbiol. 2013; 303(6-7):305-17. doi: 10.1016/j.ijmm.2013.02.008 PMID: 23490927
35. Hawkey PM, Jones AM. The changing epidemiology of resistance. J Antimicrob Chemother. 2009; 64 Suppl 1:i3-10. Epub 2009/08/19. doi: 10.1093/jac/dkp256 PMID: 19675017
36. Sheng WH, Badal RE, Hsueh PR. Distribution of extended-spectrum β-lactamases, AmpC β-lactamases, and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal infections in the Asia-Pacific region: results of the study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrob Agents Chemother. 2013; 57(7):2981-8. doi: 10.1128/aac.00971-12 PMID: 23587958; PubMed Central PMCID: PMC3697370.
37. Dudley MN, Ambrose PG, Bhavnani SM, Craig WA, Ferraro MJ, Jones RN. Background and rationale for revised clinical and laboratory standards institute interpretive criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam. Clin Infect Dis. 2013; 56(9):1301-9. doi: 10.1093/cid/cit017 PMID: 23334813
38. Hawser SP, Badal RE, Bouchillon SK, Hoban DJ, Hsueh PR. Comparison of CLSI 2009, CLSI 2010 and EUCAST cephalosporin clinical breakpoints in recent clinical isolates of Escherichia coli, Klebsiella pneumoniae and Klebsiella oxytoca from the SMART Global Surveillance Study. Int J Antimicrob Agents. 2010; 36(3):293-4. doi: 10.1016/j.ijantimicag.2010.05.012 PMID: 20598511
39. Tan TY, Ng LS, He J, Chen DM. Improved detection of AmpC β-lactamases in Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis using new susceptibility breakpoints for third-generation cephalosporins. Diagn Microbiol Infect Dis. 2011; 70(3):423-4. doi: 10.1016/j.diagmicrobio.2011.03.008 PMID: 21549542
40. Rossolini GM, D'Andrea MM, Mugnaioli C. The spread of CTX-M-type extended-spectrum β-lactamases. Clin Microbiol Infect. 2008; 14 Suppl 1:33-41. doi: 10.1111/j.1469-0691.2007.01867.x PMID: 18154526
41. Poulou A, Grivakou E, Vrioni G, Koumaki V, Pittaras T, Pournaras S, et al. Modified CLSI extended-spectrum β-lactamase (ESBL) confirmatory test for phenotypic detection of ESBLs among Enterobacteriaceae producing various β-lactamases. J Clin Microbiol. 2014; 52(5):1483-9. Epub 2014/02/28. doi: 10.1128/jcm.03361-13 PubMed Central PMCID: PMC3993656. PMID: 24574283
42. Ben-Ami R, Rodriguez-Bano J, Arslan H, Pitout JD, Quentin C, Calbo ES, et al. A multinational survey of risk factors for infection with extended-spectrum β-lactamase-producing Enterobacteriaceae in non-hospitalized patients. Clin Infect Dis. 2009; 49(5):682-90. Epub 2009/07/23. doi: 10.1086/604713 PMID: 19622043.
43. Lee CH, Lee YT, Kung CH, Ku WW, Kuo SC, Chen TL, et al. Risk factors of community-onset urinary tract infections caused by plasmid-mediated AmpC β-lactamase-producing Enterobacteriaceae. J Microbiol Immunol Infect. 2015; 48(3):269-75. Epub 2013/11/19. doi: 10.1016/j.jmii.2013.08.010 PMID: 24239065
44. Rooney PJ, O'Leary MC, Loughrey AC, McCalmont M, Smyth B, Donaghy P, et al. Nursing homes as a reservoir of extended-spectrum β-lactamase (ESBL)-producing ciprofloxacin-resistant Escherichia coli. J Antimicrob Chemother. 2009; 64(3):635-41. Epub 2009/06/25. doi: 10.1093/jac/dkp220 PMID: 19549667.
45. McDonald LC, Chen FJ, Lo HJ, Yin HC, Lu PL, Huang CH, et al. Emergence of reduced susceptibility and resistance to fluoroquinolones in Escherichia coli in Taiwan and contributions of distinct selective pressures. Antimicrob Agents Chemother. 2001; 45(11):3084-91. doi: 10.1128/aac.45.11.3084-3091.2001 PubMed Central PMCID: PMC90786. PMID: 11600360
46. Piddock LJ. Mechanisms of fluoroquinolone resistance: an update 1994-1998. Drugs. 1999; 58 Suppl 2:11-8. PMID: 10553699
47. Strahilevitz J, Jacoby GA, Hooper DC, Robicsek A. Plasmid-mediated quinolone resistance: a multifaceted threat. Clin Microbiol Rev. 2009; 22(4):664-89. doi: 10.1128/cmr.00016-09 PubMed Central PMCID: PMC2772364. PMID: 19822894
48. Labreche MJ, Frei CR. Declining susceptibilities of gram-negative bacteria to the fluoroquinolones: effects on pharmacokinetics, pharmacodynamics, and clinical outcomes. Am J Health Syst Pharm. 2012; 69(21):1863-70. doi: 10.2146/ajhp110464 PMID: 23111670
49. Poirel L, Pitout JD, Calvo L, Rodriguez-Martinez JM, Church D, Nordmann P. In vivo selection of fluoroquinolone-resistant Escherichia coli isolates expressing plasmid-mediated quinolone resistance and expanded-spectrum β-lactamase. Antimicrob Agents Chemother. 2006; 50(4):1525-7. doi: 10.1128/aac.50.4.1525-1527.2006 PubMed Central PMCID: PMC1426952. PMID: 16569874
50. Valles J, Rello J, Ochagavia A, Garnacho J, Alcala MA. Community-acquired bloodstream infection in critically ill adult patients: impact of shock and inappropriate antibiotic therapy on survival. Chest. 2003; 123(5):1615-24. PMID: 12740282
51. The American Thoracic Society and Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005; 171(4):388-416. doi: 10.1164/rccm.200405-644ST PMID: 15699079